Intelligence Feed event · Equity · 2026-10-21

    GSK gains ex-China rights to HMPL-A830

    Question

    GSK gains ex-China rights to HMPL-A830

    Direct answer

    The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “GSK gains ex-China rights to HMPL-A830”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/gsk-gains-ex-china-rights-to-hmpl-a830-06829a

    EQUITY
    GSK gains ex-China rights to HMPL-A830
    The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.
    GSK
    Impact
    64
    YESTERDAY
    SIG
    91%
    GSK
    GSK gains ex-China rights to HMPL-A830
    The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.
    → The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.
    Impact
    The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.
    Affected
    GSK
    Transmission
    The license adds pipeline optionality for GSK through a first-in-class oncology asset, with development spend and milestone exposure attached.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GSKpipeline expansion via ex-China rights to a first-in-class oncology assetMixed1-4wGSK subsidiary gained worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month